Once-Weekly Treatment Approved for Achondroplasia in Kids

(MedPage Today) — The FDA approved navepegritide (Yuviwel) for children ages 2 and older with achondroplasia, the most common form of dwarfism, developer Ascendis Pharma announced on Friday.
The prodrug of C-type natriuretic peptide (CNP) is…

Source link : https://www.medpagetoday.com/endocrinology/growthdisorders/120113

Author :

Publish date : 2026-03-02 19:09:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Once-Weekly Treatment Approved for Achondroplasia in Kids

NHS Boosts Bone Scanning With 20 New DEXA Units

Electrolyte Supplements Are Everywhere. Who Benefits From Them and When?

Related Posts

Regular Cannabis Use Linked to Symptoms of Menopause

Home-Based Neuromodulator Shows Promise for Suppressing Ventricular Arrhythmias

Study Raises Questions About Effects, Risks of Drugs for Geographic Atrophy

Sharp Drop in Bariatric Surgery; Plea to Protect Research; How to Prescribe Exercise

Brain Changes Tied to Single Psilocybin Dose; 50 Days to See Neurology; APOE4 and MS

A Look at the Safety of OX40-Targeted Therapy in Atopic Dermatitis

Regular Cannabis Use Linked to Symptoms of Menopause

Home-Based Neuromodulator Shows Promise for Suppressing Ventricular Arrhythmias

Study Raises Questions About Effects, Risks of Drugs for Geographic Atrophy

Sharp Drop in Bariatric Surgery; Plea to Protect Research; How to Prescribe Exercise

Brain Changes Tied to Single Psilocybin Dose; 50 Days to See Neurology; APOE4 and MS

A Look at the Safety of OX40-Targeted Therapy in Atopic Dermatitis

Here’s What Medical Marijuana Can Do for Older Patients

Hantavirus Cruise Ship: Plans Made for Britons Aboard

Categories

Archives